Feature | June 22, 2012

FDA Panel Does Not Recommend New ACS Indication for Xarelto

Janssen said it will work with FDA to address issues for its use in acute coronary syndromes

June 22, 2012 — The the U.S. Food and Drug Administration (FDA) Cardiovascular and Renal Drugs Advisory Committee voted in May against recommending approval of expanding the indication for rivaroxaban (Xarelto).  The drug’s maker, Janssen Research and Development LLC, wants to expand the indication to include the reduction of the risk of secondary cardiovascular events in patients with acute coronary syndrome (ACS). The FDA recently issued a response letter regarding the drug’s supplemental new drug application (sNDA), which the company is evaluating and said it will address the agency's questions.

Xarelto is approved for three clinical uses in the United States: To reduce the risk of blood clots in the legs and lungs of people who have just had knee replacement surgery, to reduce this risk in people who have just had hip replacement surgery and to reduce the risk of both hemorrhagic and thrombotic strokes as well as other blood clots in people with atrial fibrillation not caused by a heart valve problem. Janssen submitted this sNDA in December 2011 and received a priority review designation from the FDA in February.

Healthcare market research firm Decision Resources recently surveyed U.S. cardiologists and managed care organization (MCO) pharmacy directors. Respondents said reducing the incidence of mortality is the greatest unmet need in post-myocardial infarction and Xarelto is being watched as a possible pharmaceutical solution. 

“Despite the declining rate of deaths due to myocardial infarction and despite the emergence of novel antiplatelet agents and optimal statin therapy, the incidence of mortality remains the attribute that most influences surveyed cardiologists’ prescribing decisions in post-myocardial infarction,” said Decision Resources analyst Conor Walsh, Ph.D. “According to clinical data and thought leaders we interviewed, Bayer/Janssen’s Xarelto has demonstrated the potential to significantly fulfill this unmet need.”

For more information: www.janssenrnd.com

Related Content

Brilinta, 60 mg dose available, U.S. pharmacies
Technology | Antiplatelet and Anticoagulation Therapies| October 02, 2015
AstraZeneca announced that Brilinta (ticagrelor) 60-mg tablets are now available in U.S. pharmacies. On Sept. 3, 2015,...
News | Antiplatelet and Anticoagulation Therapies| September 25, 2015
The Icahn School of Medicine at Mount Sinai has launched the international TWILIGHT clinical trial to test the safety...
Brilinta, expanded indication, long-term use, FDA

Brilinta image courtesy of AstraZeneca

Technology | Antiplatelet and Anticoagulation Therapies| September 15, 2015
AstraZeneca announced that the U.S. Food and Drug Administration (FDA) has approved Brilinta (ticagrelor) tablets at a...
New Haven Pharmaceuticals, FDA approval, Durlaza, antiplatelet, once-daily, extended-release
Technology | Antiplatelet and Anticoagulation Therapies| September 11, 2015
New Haven Pharmaceuticals Inc. announced U.S. Food and Drug Administration (FDA) approval of Durlaza (aspirin) 24-hour...
News | Antiplatelet and Anticoagulation Therapies| September 08, 2015
Extending clot-preventing dual antiplatelet therapy (DAPT) beyond the recommended 12 months after coronary stenting “...
Xarelto, PMSS, XANTUS, ESC 2015, major bleeding, non-valvular atrial fibrillation, NVAF
News | Antiplatelet and Anticoagulation Therapies| September 04, 2015
Janssen Pharmaceuticals Inc. and its development partner Bayer HealthCare announced results from PMSS and XANTUS, real-...
Feature | Antiplatelet and Anticoagulation Therapies| September 01, 2015
September 1, 2015 — Extending treatment with the anticoagulant bivalirudin for at least four hours after completion o
News | Cath Lab| August 26, 2015
August 26, 2014 — The Cardiovascular Research Foundation (CRF) announced the late-breaking trials and first report in
NICE, U.K., edoxaban, Lixiana, VTE, venous thromboembolism, deep vein thrombosis, pulmonary embolism
News | Deep Vein Thrombosis| August 12, 2015
The National Institute for Health and Care Excellence (NICE) has recommended a new treatment to help patients suffering...
Boehringer Ingelheim, RE-DUAL PCI, RE-CIRCUIT, Pradaxa, first U.S. patients,
News | Antiplatelet and Anticoagulation Therapies| August 05, 2015
August 5, 2015 — Boehringer Ingelheim announced the first U.S.
Overlay Init